Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIPS-B: Budesonide and Formoterol for ARDS Prevention
NCT01783821Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2013
- Primary completion
- Jul 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of budesonide and formoterol in acute respiratory distress syndrome (ARDS), sponsored by Mayo Clinic. Primary endpoint: Change in Oxygen Saturation to Fraction of Inspired Oxygen Concentration Ratio at 5 days. Started Jul 2013; status: completed.
02
Drugs
budesonideformoterol
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT01783821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01783821.